Search
Hisun Pharmaceutical has received IND (Investigational New Drug) approval from the National Medical Products Administration for its independently developed HSK47388 tablet, a potent and highly selective oral Category 1 chemical drug. The approval paves the way for clinical trials in autoimmune diseases. Preclinical studies have demonstrated that HSK47388 exhibits notable efficacy and favorable tolerability in rat models of enteritis. Should this IND application culminate in success, it is anticipated to offer a groundbreaking treatment alternative for patients suffering from autoimmune diseases. Nonetheless, investors are reminded to approach decisions with caution, given the lengthy development cycle, complex process, and inherent risks associated with innovative drug development.
-
C114 Communication Network -
Communication Home
